Gonadotropin-releasing hormone analogue binds to luteal cells and inhibits progesterone production
- PMID: 228197
- DOI: 10.1038/282090a0
Gonadotropin-releasing hormone analogue binds to luteal cells and inhibits progesterone production
Abstract
Although gonadotropin-releasing hormone (GnRH) is believed to mediate the hypothalamic control of pituitary gonadotropin secretion, continuous or repeated administration of GnRH or its agonist analogues has been shown to cause paradoxical antifertility effects in several species, including primates. GnRH-induced interruption of reproductive cycles and pregnancy is associated with diminished progesterone production, implying defective function of the corpus luteum. These luteolytic effects have been attributed to the well recognized desensitising actions of elevated luteinising hormone (LH) levels on ovarian LH receptors and steroidogenesis, subsequent to GnRH-induced gonadotropin release from the anterior pituitary. However, treatment with high doses of exogenous LH did not cause suppression of serum progesterone levels during early pregnancy in rats, whereas a highly active GnRH analogue was effective in this regard. These observations suggested that GnRH and its agonist analogues, given in high or sustained doses, can exert a direct action on the ovary that is independent of the pituitary. This hypothesis was further supported by the ability of GnRH and its agonists to inhibit human chorionic gonadotropin (HCG)-induced ovarian and uterine weight gain in hypophysectomised rats and to delay the onset of puberty in intact female rats. Also, GnRH and its agonist analogues have recently been shown to inhibit steroidogenesis induced by follicle-stimulating hormone (FSH) in cultured granulosa cells, confirming the direct action of such peptides on the ovarian follicle. The marked inhibitory effects of GnRH and its agonists on corpus luteum function suggest that these compounds could exert direct actions by binding to specific receptors on luteal cells. The present experiments, which examine the effects of GnRH agonists on luteal steroidogenesis, demonstrate the existence of such actions and their mediation by specific high-affinity receptor sites present in luteal cell membranes.
Similar articles
-
Antigonadotropic actions of GnRH agonist on ovarian cells in vivo and in vitro.J Steroid Biochem. 1985 Nov;23(5B):765-70. doi: 10.1016/s0022-4731(85)80012-1. J Steroid Biochem. 1985. PMID: 3001418
-
Direct inhibitory effect of gonadotropin-releasing hormone upon luteal luteinizing hormone receptor and steroidogenesis in hypophysectomized rats.Endocrinology. 1980 Dec;107(6):1930-6. doi: 10.1210/endo-107-6-1930. Endocrinology. 1980. PMID: 6253282
-
Effects of gonadotropin-releasing hormone agonist on human chorionic gonadotropin activity in granulosa cells of immature female rats.J Reprod Dev. 2018 Apr 13;64(2):129-134. doi: 10.1262/jrd.2017-142. Epub 2017 Dec 15. J Reprod Dev. 2018. PMID: 29249775 Free PMC article.
-
Contraception with LHRH agonists, a new physiological approach.Reproduccion. 1981 Oct-Dec;5(4):229-41. Reproduccion. 1981. PMID: 6274723 Review.
-
Progesterone as a mediator of gonadotrophin action in the corpus luteum: beyond steroidogenesis.Hum Reprod Update. 2003 Mar-Apr;9(2):99-117. doi: 10.1093/humupd/dmg016. Hum Reprod Update. 2003. PMID: 12751773 Review.
Cited by
-
LRFD6a has a dose-related stimulatory or inhibitory effect on the ovary in normal luteal phase women.J Endocrinol Invest. 1985 Aug;8(4):297-302. doi: 10.1007/BF03348501. J Endocrinol Invest. 1985. PMID: 3934254
-
Luteinizing hormone-releasing hormone and its analogues: a review of biological properties and clinical uses.J Endocrinol Invest. 1988 Jul-Aug;11(7):535-57. doi: 10.1007/BF03350179. J Endocrinol Invest. 1988. PMID: 2902123 Review. No abstract available.
-
Progress in neuroendocrinology: LH releasing (LHRH), basic and clinical aspects.J Endocrinol Invest. 1983 Jun;6(3):243-51. doi: 10.1007/BF03350615. J Endocrinol Invest. 1983. PMID: 6311892 Review. No abstract available.
-
Gonadotropin releasing hormone analogs as part of controlled ovarian stimulation.F S Rep. 2022 Nov 21;4(2 Suppl):8-14. doi: 10.1016/j.xfre.2022.11.007. eCollection 2023 Jun. F S Rep. 2022. PMID: 37223758 Free PMC article.
-
Association of inhibin B serum levels with parameters of follicular response in a randomized controlled trial comparing gnRH agonist versus antagonist protocols for ovarian hyperstimulation.J Assist Reprod Genet. 2004 Jul;21(7):249-55. doi: 10.1023/b:jarg.0000042010.86102.03. J Assist Reprod Genet. 2004. PMID: 15526982 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
